PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer

This phase Ib trial tests the safety, side effects, and best dose of autologous anti-prostate stem cell antigen (PSCA)-chimeric antigen receptor (CAR)-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes (PSCA-CAR T cells), plus or minus radiation, in treating patients with castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Castration-resistant prostate cancer continues to grow and spread despite the surgical removal of the testes or medical intervention to block androgen production. CAR T-cell therapy is a type of

Trial Details

NCT ID

NCT05805371

Phase

PHASE1

Sponsor

City of Hope Medical Center

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
Biopsy
Biospecimen Collection
Bone Scan
Computed Tomography
External Beam Radiation Therapy

Locations (sample)

Duarte, California, United States|34.13945,-117.97729

Key Eligibility Criteria

Documented informed consent of the participant and/or legally authorized representative (brown)
Assent, when appropriate, will be obtained per institutional guidelines
Note: For research participants who do not speak English, a short form consent may be used with a City of Hope (COH) certified interpreter/translat…
Agreement to allow the use of archival tissue from diagnostic tumor biopsies

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →